NDA 220359 · Astrazeneca
Etcamah
Camizestrant · Oral
NovelCDER novel approval, Sep 4, 2026: To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Sep 4, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
16
6 Phase 3, 5 recruiting
FAERS reports
14
13 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ARRHYTHMIA RISK WITH CONCOMITANT USE OF QTc INTERVAL PROLONGING DRUGS ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death ( 5.1 , 5.2 , 7.1 ). Avoid concomitant use of ETCAMAH with products (other than ribociclib) known to prolong the QTc interval and/or have a known risk of Torsades de Pointes. If concomitant use with other products cannot be avoided, monitor the QTc interval more frequently ( 5.1 , 7.3 ). Obtain ECG prior to initiation and monitor heart rate and QTc interval during treatment. Assess and correct electrolyte abnormalities prior to initiation and during treatment. Withhold ETCAMAH until resolution of QTc interval prolongation and resume or permanently discontinue...
What it is approved for
From the label in effect Sep 4, 2026.
ETCAMAH in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test [see Dosage and Administration ( 2.1 )] . This indication is approved under accelerated approval based on progression-free survival as measured from detection of ESR1 mutation [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ETCAMAH is an estrogen receptor antagonist indicated: • in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA authorized test. ( 1 , 2.1 ) This indication is approved under accelerated approval based on progression-free survival as measured from detection of ESR1 mutation. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )
Mechanism: Camizestrant is an estrogen receptor (ER) antagonist. In vitro, camizestrant binds to the ligand binding domain of ERα, antagonizing the activity of ERα encoded by both wild-type ESR1 and mutated ESR1 and inducing proteasome-dependent degradation of ERα, without agonizing ERα. Camizestrant demonstrated anti-tumor activity in ER-positive cell lines, in vitro, and patient derived xenograft (PDX) models, in vivo, including those with wild-type or mutated ESR1 genes. Treatment with camizestrant and CDK4/6 inhibitors (abemaciclib, palbociclib, or ribociclib) demonstrated greater anti-tumor...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ETCAMAH · CAMIZESTRANT 75MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Camizestrant" as an intervention, any sponsor and status, largest first.
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05952557 · 5,511 participants · Start Oct 5, 2023 · Primary completion Mar 4, 2030
Drug: Camizestrant; Tamoxifen and 4 more · For: Breast Cancer, Early Breast Cancer
Sites: Dothan, Alabama; Phoenix, Arizona; Tucson, Arizona · 661 sites in all
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05774951 · 4,300 participants (planned) · Start Mar 31, 2023 · Primary completion Apr 20, 2027
Drug: Camizestrant; Tamoxifen and 3 more · For: Breast Cancer, Early Breast Cancer
Sites: Birmingham, Alabama; Dothan, Alabama; Anchorage, Alaska · 709 sites in all
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseasePivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04711252 · 1,371 participants · Start Jan 28, 2021 · Primary completion Jun 26, 2026
Drug: AZD9833; Anastrozole and 4 more · For: ER-Positive HER2-Negative Breast Cancer
Sites: Mobile, Alabama; Springdale, Arkansas; Harbor City, California · 263 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06380751 · 788 participants (planned) · Start Aug 1, 2024 · Primary completion Dec 18, 2029
Drug: Saruparib (AZD5305); Camizestrant and 7 more · For: Advanced Breast Cancer
Sites: Gilbert, Arizona; Fountain Valley, California; Glendale, California · 306 sites in all
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04644068 · 702 participants · Start Nov 12, 2020 · Primary completion May 28, 2027
Drug: AZD5305; Paclitaxel and 4 more · For: Ovarian Cancer; Breast Cancer; Pancreatic Cancer and 10 more
Sites: Boston, Massachusetts; New York, New York; Oklahoma City, Oklahoma · 68 sites in all
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03616587 · 396 participants · Start Oct 11, 2018 · Primary completion Sep 16, 2024
Drug: AZD9833; AZD9833 and 12 more · For: ER+ HER2- Advanced Breast Cancer
Sites: Aurora, Colorado; Sarasota, Florida; Philadelphia, Pennsylvania · 17 sites in all
- Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04964934 · 315 participants · Start Jun 30, 2021 · Primary completion Jun 30, 2025
Drug: AZD9833; AZD9833 Placebo and 8 more · For: ER-Positive HER2-Negative Breast Cancer
Sites: Phoenix, Arizona; Hot Springs, Arkansas; Little Rock, Arkansas · 264 sites in all
- A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04214288 · 240 participants · Start Apr 22, 2020 · Primary completion Aug 30, 2022
Drug: AZD9833; Fulvestrant · For: Advanced ER-Positive HER2-Negative Breast Cancer
Sites: Birmingham, Alabama; Long Beach, California; Fort Myers, Florida · 85 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hydronephrosis3
- fatigue2
- nausea2
- off label use2
- periorbital swelling2
- abdominal distension1
- acute kidney injury1
- alanine aminotransferase increased1
- altered state of consciousness1
- ammonia increased1
- arrhythmia1
- arthralgia1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 5 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.
Bidard FC, Mayer EL, Park YH, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
Hamilton E, Oliveira M, Turner N, et al. · Ann Oncol 2024 · Clinical Trial, Phase I, Multicenter Study
- Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.
Turner NC, Mayer EL, Park YH, et al. · Lancet Oncol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.
Baird RD, Bermejo de Las Heras B, Ruiz-Borrego M, et al. · Clin Cancer Res 2025 · Clinical Trial, Phase I, Multicenter Study
- Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial.
Oliveira M, Pominchuk D, Nowecki Z, et al. · Lancet Oncol 2024 · Clinical Trial, Phase II, Randomized Controlled Trial
- SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.
Brufsky A, Park YH, Bidard FC, et al. · Oncologist 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.